Prostatype Genomics Past Earnings Performance
Past criteria checks 0/6
Prostatype Genomics's earnings have been declining at an average annual rate of -33.9%, while the Biotechs industry saw earnings growing at 13.6% annually. Revenues have been declining at an average rate of 0.3% per year.
Key information
-33.9%
Earnings growth rate
26.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -0.3% |
| Return on equity | -305.1% |
| Net Margin | -985.2% |
| Next Earnings Update | 13 Feb 2025 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Prostatype Genomics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 4 | -41 | 18 | 2 |
| 31 Mar 24 | 4 | -43 | 19 | 3 |
| 31 Dec 23 | 4 | -41 | 18 | 3 |
| 30 Sep 23 | 3 | -40 | 17 | 3 |
| 30 Jun 23 | 1 | -37 | 14 | 4 |
| 31 Mar 23 | 1 | -31 | 12 | 3 |
| 31 Dec 22 | 1 | -29 | 10 | 4 |
| 30 Sep 22 | 1 | -27 | 10 | 3 |
| 30 Jun 22 | 1 | -23 | 9 | 2 |
| 31 Mar 22 | 2 | -18 | 8 | 2 |
| 31 Dec 21 | 3 | -16 | 8 | 1 |
| 30 Sep 21 | 3 | -14 | 7 | 1 |
| 30 Jun 21 | 3 | -14 | 7 | 0 |
| 31 Mar 21 | 3 | -15 | 7 | 1 |
| 31 Dec 20 | 3 | -14 | 6 | 2 |
| 30 Jun 20 | 3 | -9 | 5 | 2 |
| 30 Jun 19 | 3 | -9 | 5 | 1 |
| 30 Jun 18 | 5 | -9 | 5 | 3 |
| 30 Jun 17 | 5 | -5 | 2 | 2 |
| 30 Jun 16 | 0 | -11 | 3 | 2 |
Quality Earnings: PGO is currently unprofitable.
Growing Profit Margin: PGO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PGO is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.
Accelerating Growth: Unable to compare PGO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PGO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.6%).
Return on Equity
High ROE: PGO has a negative Return on Equity (-305.15%), as it is currently unprofitable.